Search filters

List of works by Felipe Samaniego

90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease

scientific article

A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma

scientific article published on 5 April 2018

Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma

scientific article published on 24 June 2019

Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study

scientific article published on 16 October 2020

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

scientific article

Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma

scientific article published on 6 August 2015

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

scientific article published on 05 October 2020

Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

scientific article published on 01 August 2020

De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era

scientific article published on 18 September 2019

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

scientific article

Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes

scientific article published on 26 February 2019

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients

scientific article published on 02 April 2020

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

scientific article

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma

scientific article published on 18 May 2017

Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma

scientific article published on 27 March 2015

Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma

scientific article published on 01 May 2019

Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)

scientific article published on 22 May 2018

Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma

scientific article published on 06 March 2019

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma

scientific article published on 30 July 2020

High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study

scientific article published on 24 March 2017

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

scientific article published on 27 November 2015

Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement

scientific article published on 10 July 2020

Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma

scientific article published on 06 July 2020

Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma

scientific article published on 14 September 2020

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

scientific article

Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial

scientific article published on 28 March 2019

Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy

scientific article published on 03 April 2019

Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma

scientific article published on 15 September 2020

Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma

scientific article published on 28 February 2019

Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.

scientific article published on 28 June 2016

Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy.

scientific article

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

scientific article published on 08 July 2014

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial

scientific article

Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.

scientific article published on 31 March 2015

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

scientific article

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

scientific article

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

scientific article published on 3 May 2018

Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma

scientific article published on 26 April 2011

Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma

scientific article

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma

scientific article

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

scientific article published on 27 July 2015

Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma

scientific article published on 29 June 2007

Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.

scientific article published on 9 August 2017

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

scientific article published on 10 October 2019

Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

scientific article published on 23 January 2020

Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma

scientific article published on 01 May 2019

Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.

scientific article published on 22 July 2016

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

scientific article published on October 2013

Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center

scientific article

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

scientific article

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

scientific article

Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection

scientific article published on 17 May 2019

Targeting Wnt pathway in mantle cell lymphoma-initiating cells.

scientific article published on 6 June 2015

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

scientific article published on 06 January 2014

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma

scientific article published on 14 March 2018

The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.

scientific article

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

scientific article published on 3 April 2017

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

scientific article published on 21 February 2018

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

scientific article published on 19 March 2019

Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial

scientific article published on 29 December 2012

Paulina is supported by:

About Paulina

Help